Injective
Why Injective is down 1.6% in the last hour
Analysis
Injective (INJ) slipped 1.6% over the past hour, likely reflecting short-term profit-taking or a muted market reaction after earlier optimism tied to ETF-related commentary. The move comes as *The Block* reported Injective CEO Eric Chen said he expects US INJ ETFs to launch sooner than 2027, but the headline did not translate into immediate upside in this timeframe.
Contributing Factors (1)
Injective CEO Eric Chen expects US INJ ETFs to launch sooner than 2027
There are currently two ETF applications tied to INJ — the 21Shares Injective ETF and the Canary Staked INJ ETF.
Move Details
Explanation Confidence
High confidence in the explanation based on source reliability and timing.